Symbiotec Pharmalab Ltd
SYMBIOTECPharmaceuticals - Indian - Bulk Drugs & Formln
₹1,092.80
₹-4.90 (-0.45%)
Closed · As of 2 Sept 3:30 pm
Mkt Cap
₹7,042 Cr
P/E
48.28
ROE
—
ROCE
—
Symbiotec Pharmalab Ltd
SYMBIOTECPharmaceuticals - Indian - Bulk Drugs & Formln
₹1,092.80₹-4.90 (-0.45%)
Closed · As of 2 Sept 3:30 pm
Market Cap
7,042 Cr
P/E Ratio
48.28
ROE
—
ROCE
—
About Symbiotec Pharmalab Ltd
Company description not available.
Founded
N/A
CEO
N/A
Employees
N/A
HQ
N/A
Finished Products
No finished products reported
This company hasn’t disclosed any finished products breakdown.
Raw Materials
No raw materials reported
This company hasn’t disclosed any raw materials breakdown.
About Symbiotec Pharmalab Ltd
Company description not available.
Founded:N/A
CEO:N/A
Employees:N/A
HQ:N/A
Finished Products
No finished products reported
This company hasn’t disclosed any finished products breakdown.
Raw Materials
No raw materials reported
This company hasn’t disclosed any raw materials breakdown.
Price Performance & Market EventsPrice Performance
Loading chart data…
Key Metrics
Trading & valuation snapshot
52W High
₹1,180
52W Low
₹934
Volume8.00M
Avg VolumeN/A
BetaN/A
Dividend Yield0.00%
Key Financial Ratios
Profitability, leverage & efficiency at a glance
P/E Ratio
48.28x
Valuation
P/B Ratio
5.61x
Valuation
EPS
₹22.70
Valuation
Dividend Yield
0.00%
Valuation
ROE
0.00%
Profitability
ROCE
N/A
Profitability
Revenue by Segment
Contribution & growth by business line
No segment revenue data available
Geographical Revenue Split
Domestic vs international exposure
Domestic
0.0%
International
0.0%
No geographic split data available
Strategic Relations
Collaborations, joint ventures & subsidiaries
No collaborations data available.
Forensic Metrics
Financial health & earnings-quality indicators
Revenue Quality
N/A
Days Sales Outstanding
Leverage
0.00x
Debt-to-Equity
Earnings Quality
N/A
Cash Conversion Ratio
Efficiency
N/A
Asset Turnover
Earnings Quality
N/A
Accruals Ratio
Profitability
N/A
Gross Margin
Growth
6.7%
Sales Growth
These metrics are derived from available financial disclosures and market data. Use them together with company filings and qualitative analysis before making decisions.